GayWebSource.com – LGBTQ News And Press Release Syndication. Connecting Gay News Media Worldwide Since Nov. 2001, Over 20 Yrs Serving the Gay Community.
Submit New Post < You must use this link to submit your content manually. If you are posting on your wall or using the feedly rss feed. It stays on your wall and not into our syndication
<p>HIV drug increases risk of suicidal ideation.</p>
<p><a href="http://www.thegayuk.com/ClovisPalmer">by Doctor Clovis Palmer </a>| 21st September 2014</p><p></p><p>
</p><p><img src="http://www.thegayuk.com/communities/8/004/009/928/388/images/4599094445.jpg" width="460" height="305" alt="" title="" /></p>
<p></p><p>A recent study shows an association between <a href="http://en.wikipedia.org/wiki/Efavirenz">Efavirenz</a> (a common anti-HIV drug) and increased risk for suicidal ideation or attempted or completed suicide. The study conducted by Mollan KR et al., and published in Ann Intern Med. 2014 <a href="https://www.google.co.uk/search?q=Mollan+KR%2C+et+al.+Annals+of+Internal+Medicine.+2014%3B+161%3A+1-10&oq=Mollan+KR%2C+et+al.+Annals+of+Internal+Medicine.+2014%3B+161%3A+1-10&aqs=chrome..69i57.291j0j4&sourceid=chrome&es_sm=91&ie=UTF-8">confirmed the neuropsychiatric effects of Efavirenz</a>. With increased life expectancy of people living with HIV infection - and the opportunity to study the long term effects of drugs - the emergence of drug-induced co-morbidities is concerning. </p><p></p><p>This underscores the need for the development of longer-acting drugs or treatment modalities that limit the constant (daily) use of antiretroviral therapy. Emerging data also beg the question as to the longer-term benefits of immediate treatment of a young individual with normal <a href="http://www.google.com/cse?cx=000720862908139971006:xoz-qqbjqgy&q=CD4%20T&oq=CD4%20T&gs_l=partner.3...60061.62965.1.64088.5.5.0.0.0.0.112.401.3j2.5.0.gsnos%2Cn%3D13...0.3023j2527639j8..1ac.1.25.partner..7.4.389.3Z3o8o7452Q#gsc.tab=0&gsc.q=CD4%20T&gsc.page=1">CD4 T</a> cell count and low viral load.</p><p></p><p>Indeed, early treatment reduces inflammation and impacts the size of the viral reservoir - yet the clinical benefits are questionable. </p><p></p><p>One argument for early treatment is epidemiological-based: “to protect the community”. But we probably can dismiss this one because with fashionable PrEP picking up steam we might all be chewing <a href="http://www.google.com/cse?cx=000720862908139971006:xoz-qqbjqgy&q=PrEP&oq=PrEP&gs_l=partner.3...331028.332498.0.332735.6.5.1.0.0.0.197.526.3j2.5.0.gsnos%2Cn%3D13...0.1463j633987j8j1..1ac.1.25.partner..3.3.282.z2PS-5JzZPk#gsc.tab=0&gsc.q=PrEP&gsc.page=1">PrEP</a> candies in the near future. </p><p></p><p>I think more needs to be done to delay the use of antiretroviral drugs wherever possible, and more reliable measures of inflammation are needed so that we are not only guiding treatment based on CD4 cell counts and viral load but also take into account the levels of inflammation a person has. After all, inflammation (which generally is associated with CD4 T cell count) has been shown to be the best predictor of HIV disease progression and mortality.</p><p></p><p>Dr Clovis Palmer is a graduate of the University of Sydney, Australia, and holds a PhD in plant biochemistry and molecular genetics. He conducted postdoctoral studies in immunology, liver disease and obesity at the University of New South Wales, Australia. </p><p></p><p>Dr Palmer is a reviewer for several top ranked international journals including Hepatology, AIDS and Antioxidants and Redox Signalling. He is the chief scientific editor for Natural Immunity-Health, Australia (<a href="http://www.naturalimmunity.com.au/">www.naturalimmunity.com.au</a>).</p><p></p><p></p><p></p><p>
</p><p><img src="http://www.thegayuk.com/communities/8/004/009/928/388/images/4611476916.jpg" width="460" height="30" alt="" title="" /></p>
<p><a href="http://www.thegayuk.com/magazine/4574334751/Life-Assurance-Policies-Up-140-For-People-Living-With-HIV/8596296">Life Assurance Policies Up 140% For People Living With HIV</a></p><p><a href="http://www.thegayuk.com/magazine/4574334751/NEWS-Dates-For-National-HIV-Testing-Week-Announced/8778293">Dates For National HIV Testing Week Announced</a></p><p><a href="http://www.thegayuk.com/magazine/4574334751/HIV-Death-Rates-Halved-Since-1999/8476911">HIV Death Rates Halved Since 1999</a></p>
A recent study shows an association between Efavirenz (a common anti-HIV drug) and increased risk for suicidal ideation or attempted or completed suicide. The study conducted by Mollan KR et al., and published in Ann Intern Med. 2014 confirmed the neuropsychiatric effects of Efavirenz. With increased life expectancy of people living with HIV infection - and the opportunity to study the long term effects of drugs - the emergence of drug-induced co-morbidities is concerning.
This underscores the need for the development of longer-acting drugs or treatment modalities that limit the constant (daily) use of antiretroviral therapy. Emerging data also beg the question as to the longer-term benefits of immediate treatment of a young individual with normal CD4 T cell count and low viral load.
Indeed, early treatment reduces inflammation and impacts the size of the viral reservoir - yet the clinical benefits are questionable.
One argument for early treatment is epidemiological-based: “to protect the community”. But we probably can dismiss this one because with fashionable PrEP picking up steam we might all be chewing PrEP candies in the near future.
I think more needs to be done to delay the use of antiretroviral drugs wherever possible, and more reliable measures of inflammation are needed so that we are not only guiding treatment based on CD4 cell counts and viral load but also take into account the levels of inflammation a person has. After all, inflammation (which generally is associated with CD4 T cell count) has been shown to be the best predictor of HIV disease progression and mortality.
Dr Clovis Palmer is a graduate of the University of Sydney, Australia, and holds a PhD in plant biochemistry and molecular genetics. He conducted postdoctoral studies in immunology, liver disease and obesity at the University of New South Wales, Australia.
Dr Palmer is a reviewer for several top ranked international journals including Hepatology, AIDS and Antioxidants and Redox Signalling. He is the chief scientific editor for Natural Immunity-Health, Australia (www.naturalimmunity.com.au).
New Members: If You Just Created A New Account, Please Upload A Logo or A Photo To Represent You or Your Publication. All new accounts must have an avatar pic. We will not approve your account until your profile has been competed. You will not have full access of the site until your account is approved. We require this to help keep out spam accounts. To edit your profile, click on your name in the top right corner of the site and follow the profile links. If Your Account Has Been Recently Migrated Please Click = > Here.
More Stories
1 Song for Equality and Peace by Craymo
Gay Film Weekend Banned In 1,100 Catholic Owned Cinemas In Italy
Big Brother’s Aaron Frew Leaves Nothing To The Imagination With Completely Naked Shot